Ascendis Pharma will share sentinel cohort data from its reACHin pivotal trial of navepegritide in infants under two at ESPE 2026.

The Nasdaq-listed oncology company has detailed patents covering APR-1051 and ATRN-119, with WEE1 protection potentially running to 2047.

Nokia's Network as Code platform replaces SMS one-time passcodes for BeeHealthy, a white-label health SaaS serving providers across Europe and the Middle

AMS posted 19% year-on-year Q2 revenue growth to $8.4m, led by a 40% surge in direct patient services across its US and

The NASDAQ-listed MWA device maker posted $9.9m in first-half revenue, with the US now accounting for 27% of sales versus under 2

An injectable synthetic bone void filler from Biomimetic Innovations was used in a tibial plateau fracture repair at the University of Leeds, marking the start

Cytek will present Full Spectrum Profiling technology at two clinical cytometry conferences in September and October, with a focus on MRD monitoring.

The NASDAQ-listed operator said paid membership surged 40% to over 210,000 in under seven weeks, as it builds toward an AI-enabled care

A post-hoc item-level analysis found domain-specific cognitive gains three months after treatment in half of evaluable active-arm participants.

The NASDAQ-listed RNAi oncology biotech will use net proceeds to advance its Phase 2/3 SIL204 trial in locally advanced pancreatic cancer.

S&P's upgrade to BBB- means Teva now holds investment-grade ratings from all three major agencies, capping a multi-month credit rehabilitation.

Pulmovant will share Phase 2 results for inhaled sGC activator mosliciguat in PH-ILD at ERS Congress on 8 September 2026.